Trademark and controlled-substance symbols do not count as intervening matter

DisputednoteFDA guidance · non-bindingCheckable — presence or a literal match settles it

Rule

FDA does not treat trademark symbols (®, ™) or controlled-substance symbols (e.g., CII) next to the proprietary name as intervening matter that separates the proprietary and established names.

Check

If a trademark or controlled-substance symbol sits between the proprietary and established name, do not flag it as prohibited intervening matter on that basis alone.

Where this comes from

Section II.A · page 6. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…d the established name not be separated by placement of intervening matter that would in any way detract from, obfuscate, or de-emphasize the established name of the product or obscure the relationship between the proprietary name and the established name. For example, FDA recommends that the proprietary and established names not be separated by intervening matter, such as a logo, tagline, or other graphics. Note: FDA does not consider trademark symbols associated with proprietary names (e.g., registered trademark symbols (®) or unregistered trademark symbols (™)) or controlled substance symbols (e.g., CII) to be intervening matter. Examples of appropriate juxtaposition include, but are not limited to, the following: PROPRIETARY NAME® (established name) logo PROPRIETARY NAME™ (established name) PROPRIETARY NAME® CII (established name) B. Size of Proprietary and Established Names When the established name is required to accompany the proprietary name in the running text of promotional labeling and advertisements, the regulations also re…

Open the original at page 6 on fda.gov ↗Read our full copy →

Document: FDA guidance: Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling (final)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: f6f78606542ef91596ef21f6…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

How this rule was checked

The verifier and drafter could not agree. Waiting for a human decision — not used in reviews.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — reject
claude-code:opus · 2026-09-21
Reviewer's reasons
- The statement is faithful to the source — Section II.A's Note says FDA does not consider trademark symbols (®, TM) or controlled substance symbols (e.g., CII) to be intervening matter — but faithfulness is not the problem.
- This is a carve-out describing what the guidance does NOT require, not a requirement. No promotional piece can violate it: its check instructs the reviewer to refrain from flagging ('do not flag it as prohibited intervening matter on that basis alone'). There is no condition under which it produces a finding, so it is not something a reviewer can check as a rule.
- As a standalone corpus entry it is also a trap: a reviewer scanning rule titles could read 'Trademark and controlled-substance symbols do not count as intervening matter' as a standalone permission and miss that it is an exception to the direct-conjunction requirement it qualifies.
- The content is worth keeping — but as an exception clause inside the rules it modifies (US-NAME-018 juxtaposition and US-NAME-022 intervening matter), not as its own rule.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — reject
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is accurate and complete, but it is an interpretive carve-out: it states what FDA does NOT consider intervening matter. No promotional piece can violate it; its only function is to limit the Section II.A recommendation that the proprietary and established names not be separated by intervening matter (logo, tagline, other graphics).
- The Check itself confirms this: it tells the reviewer what not to flag, rather than defining a failure condition.
- The same carve-out also applies to the Section III active-ingredient juxtaposition recommendation ('As noted in section II.A...').

Nearby rules

US-NAME-021 US-NAME-022